DNA adduct burden and tobacco carcinogenesis

Abstract

DNA adducts associated with tobacco smoking could provide a marker of biologically effective dose of tobacco carcinogens and improve individual cancer risk prediction. A significant number of clinical and epidemiologic studies have reported associations of increased DNA adduct levels with the occurrence of the prevalent tobacco related cancers including cancer of the lung, head and neck, and bladder. The inducibility of DNA adducts following in vitro treatments using blood lymphocytes also appears to be a risk factor in the development of lung and head and neck cancer. Corroborative evidence pointing to the importance of DNA adducts in tobacco carcinogenesis include numerous studies showing associations of tobacco smoke exposure with the induction of DNA adducts in humans in vivo. Further effort is necessary, however, to more fully characterize the dose–response relationship between smoking and DNA adducts in exposed target and surrogate tissues. The relationship between gene polymorphisms thought to modify tobacco-related cancer risk and DNA adduct levels is complex. Results of some DNA adduct studies (both in vitro and in vivo) appear inconsistent with the epidemiologic findings. This is evident for polymorphisms involving both carcinogen metabolism (e.g. GSTP1) and DNA repair (e.g. XRCC1). Molecular studies of human tumors suggest associations of p53 mutation with DNA adducts and have revealed correlations of DNA adduct levels with somatic alterations (e.g. 3p21 LOH) that are thought to occur at the very earliest stages of tobacco carcinogenesis. More research is needed to assess the relationship between endogenous sources of DNA adducts and tobacco smoke exposure and the relative oncogenic effects of chemically stable versus unstable DNA adducts. Many potentially fruitful new avenues of cancer research are emerging that integrate DNA adduct analyses with assessments of smoking, genetics, diet and ambient air quality. These investigations aim to understand the multifactorial nature of interindividual variability in response to tobacco carcinogens. As these trends continue a variety of innovative study designs and approaches will become important in human populations.

Background

Introduction

DNA adducts are physical complexes formed between reactive chemical species and sites within the DNA molecule. DNA adducts have been proposed as potential markers of ‘biologically effective dose’ from exposure to tobacco carcinogens that may help to provide an integrated measure of carcinogen exposure relevant to individual cancer risk assessment. The emphasis of this review is on human in vivo studies except where model in vitro or animal studies are relevant to a specific issue. This review emphasizes literature appearing since 1998; below are cited reviews of earlier literature. The field of investigation that addresses DNA modifications in human cancer is expansive. This review is restricted to epidemiologic and clinical studies that address five areas bearing on the etiologic role of DNA adducts in tobacco carcinogenesis:

  1. 1)

    The evidence that genetic polymorphisms implicated in tobacco related cancers modify DNA adduct concentrations in human tissues;

  2. 2)

    The evidence that DNA adducts are risk factors in the development of tobacco related cancers;

  3. 3)

    The association of DNA adducts with molecular alterations involving oncogenes and tumor suppressor genes in human tumors;

  4. 4)

    The potential importance of endogenous and chemically unstable DNA adducts in tobacco carcinogenesis; and

  5. 5)

    Methodologic issues that affect the validity of investigations into the role of DNA adducts in tobacco carcinogenesis.

Recent reviews

Several recent reviews have addressed the use of DNA adducts in risk assessment and toxicology studies (van Delft et al., 1998a; Vainio, 1998; Timbrell, 1998; Kriek et al., 1998; Garner, 1998; Carmichael, 1998; Hemminki et al., 2001). Other reviews emphasize the chemistry of adduct formation and laboratory methodology (Phillips et al., 2000; Reddy, 2000; Szeliga and Dipple, 1998). Although most recent studies have employed only a few analytical approaches (i.e. 32P-postlabeling or immunologically based assays), new technologies and improved applications have also been reviewed (Turteltaub and Dingley, 1998, accelerated mass spectrometry); (Marzilli et al., 2001, capillary-electrophoresis-mass spectrometry); (Shinozaki et al., 1998, flow cytometry); (Ni et al., 1998, electrospray tandem mass spectrometry); (Petruzzelli et al., 1998, serum BPDE-DNA antibodies by ELISA); (Bucci et al., 1998, competitive ELISA); (Xing et al., 2001, capillary electrophoresis); (Tan et al., 2001, immunoelectrophoresis with laser induced fluorescence).

Genetic susceptibility

Previous reviews of genetic polymorphisms have assessed the potential for adducts to provide an intermediary tool for genotyping studies (Hemminki et al., 2000). The relationship of genotype to adduct formation in determining risk for lung, esophagus and oral cancer have been evaluated (Bartsch et al., 1998). An overall weight of evidence approach concluded that under conditions giving rise to detectable PAH–DNA adducts levels in tissues, most studies reviewed reported a significant role for GSTM1 deletion either alone or in combination with CYP1A1 variants on variations in adduct levels and urinary metabolites of genotoxic substances (Pavanello and Clonfero, 2000).

Metabolic polymorphisms

Glutathione S-transferases and cytochrome P4501A1

Although early studies suggested a role of GSTM1 deficiency in aromatic-hydrophobic DNA adduct levels (Ryberg et al., 1994; Grinberg-Funes et al., 1994; Shields et al., 1993; Kato et al., 1995) these studies were criticized (Cuzick, 1995) for not defining cigarette smoking exposure adequately and for not having sufficient size to adjust for potential statistical artifacts. Continued work on the GSTs has appeared (Table 1) and more recent studies have included polymorphism of the GSTT1 and GSTP1 genes. The GSTP1 isoforms could be particularly relevant in lung carcinogenesis as GSTP1 is highly expressed in lung and shows high activity in detoxifying diol epoxides of PAHs. Human GSTP1 expression in cell culture has been shown to be very effective in preventing the formation of BPDE–DNA adducts produced in vitro (Fields et al., 1998). Two common polymorphisms in GSTP1 give rise to four genotypic variants in human populations. Although allelic variants (i.e. A313G; Ile105Val) show reduced enzyme activity toward the model substrate 1-chloro-2,4-dinitrobenzene (Watson et al., 1998) when transfected into human HepG2 cells these variants were shown to provide greater protection against the formation of (+)-anti-BPDE–DNA adducts (Hu et al., 1999) compared with the wildtype GSTP1 isoform. The wildtype GSTP1 contains isoleucine at position 105. Catalytic properties of both recombinant and native variants of GSTP1 enzymes were compared with wildtype forms and the variants were shown to display greater catalytic efficiency towards carcinogenic PAHs (Coles et al., 2000a). Lung, bladder and esophageal cancer risk, however, have been associated with GSTP1 genotypes presumed to result in greater not less PAH detoxification (Ryberg et al., 1997; Kihara and Noda, 1999; Harries et al., 1997; van Lieshout et al., 1999).

Table 1 Genetic polymorphisms and DNA adducts levels

DNA adduct studies thus far have not fully resolved this apparent anomaly. In studies of newborns, PAH–DNA adducts were marginally higher among subjects with the GSTP1 Ile/Val and Ile/Ile genotypes compared with the GSTP1 Val/Val genotype (Whyatt et al., 2001). Similarly, the lowest levels of DNA adducts were observed among non-smoking women carrying the GSTP1 Val/Val genotype (Grzybowska et al., 2000) compared to others, but in occupationally exposed populations no effect of the GSTP1 polymorphism by itself has been reported on variations in PAH–DNA adduct levels (Zhang et al., 2000; Viezzer et al., 1999; Grzybowska et al., 2000; Schoket et al., 2001). The GSTP1 polymorphism was also not found to be not predictive of PAH–DNA adduct levels in bronchial tissues of lung cancer patients (Ozawa et al., 1999).

There have been suggestions of interactions between GSTP1 and other polymorphisms, but again the picture is far from clear. Whereas PAH–DNA adducts in occupationally exposed workers were elevated in GSTM1 null subjects and in persons carrying a combined GSTM1 null and GSTP1 variants (Schoket et al., 2001), another study of cigarette smokers found evidence of the GSTM1 non-null genotype interacting with GSTP1 variants and being associated with elevated DNA adducts (Butkiewicz et al., 2000). A suggested interaction of the MspI variant of CYP1A1 with the GSTP1 Val/Val genotype on adduct levels in newborns was reported in one study (Whyatt et al., 2001). It has been proposed (Coles et al., 2000b) that GSTP1 like GSTM1 is coordinately regulated with the GSTM3 locus. However, GSTM3 genotypes were not found to affect the relationship of GSTP1 with lung cancer in a recent study of 389 lung cancer cases and 353 controls in Germany (Risch et al., 2001).

A re-examination of GSTP1 genotype–phenotype relationships (Sundberg et al., 2002) has suggested that the GSTP1 enzyme containing valine at position 105 may actually have less than, or at most equal activity in reducing, PAH–DNA adduct formation compared with the wildtype GSTP1 Ile105/Ala114 isoform. The authors caution against extrapolating catalytic information from pure enzymes to the complex situation within the intact cell. Notably, they found only about 1–2% of the expected rate of BPDE conjugation to be observed in vivo in cells, which the authors postulate may be a result of the reduced concentrations of lipophilic substrates available for conjugation by the soluble GSTs (Sundberg et al., 2002).

Among coke oven workers the GSTM1 null genotype was associated with adducts among highly PAH exposed groups but GSTT1 null subjects, who are deficient in GSTT1 mediated GSH conjugation, demonstrated lower not higher adduct burdens (Viezzer et al., 1999). Negative studies have also appeared in which adduct levels in non-tumorous lung or blood MNCs were not modified by GSTM1 (Wiencke et al., 1999). Although several analytic factors have been discussed in regards to discordant results (Phillips and Castegnaro, 1999), some studies point to factors in the diet that may influence these types of comparisons. For example, GSTM1 null smokers were reported to have higher adduct levels compared with non-null smokers, and these associations were found to be modified by plasma antioxidants (Wang et al., 1998b). DNA adducts were found higher in GSTM1 null subjects in the EPIC–Italy study, and were inversely associated with the consumption of fresh fruit, vegetables, olive oil and antioxidants (Palli et al., 2000). Earlier studies suggested an important role for dietary antioxidants on DNA adduct results in smokers (Grinberg-Funes et al., 1994; Mooney et al., 1997). Given the significant role dietary constituents are now thought to play in lung cancer (Williams and Sandler, 2001) further work in this area is needed. Such information may help to improve preventive strategies involving anti-oxidants and dietary interventions (Saha et al., 2001; Jacobson et al., 2000).

Expression of CYP1A1 as assessed by mRNA levels in lung tissue was shown to be positively correlated with variations in hydrophobic-DNA adduct levels in currently smoking lung cancer patients (Mollerup et al., 1999). Earlier work showed a strong correlation of microsomal aryl hydrocarbon hydroxylase activity in lung with BPDE–DNA adduct levels (Alexandrov et al., 1992). The importance of CYP1A1 gene polymorphisms and other CYP related gene polymorphisms in adduct formation is more ambiguous. Polymorphisms at the CYP1A1 locus were not associated with variations in adduct levels in occupationally exposed workers (Schoket et al., 2001; Grzybowska et al., 2000; Zhang et al., 2000; Pan et al., 1998; Motykiewicz et al., 1998), nor in lung cancer patients (Schoket et al., 1998; Wiencke et al., 1999). One small study of adducts in lung cancer patients, however, did suggest an interaction of the GSTM1 null genotype with homozygosity of the CYP1A1 MspI variant (Rojas et al., 1998). Several studies have reported CYP1A1 variants to be associated with higher adduct levels in newborn blood and placental tissues (Whyatt et al., 1998, 2001).

Despite years of study, the role of CYP1A1 gene polymorphisms in PAH activation remains unclear. The notion that DNA adduct studies in vivo among smokers and occupationally exposed populations or patients with smoking related cancers could help to elucidate the toxicologic functionality of CYP polymorphisms has not yet been proven valid. The unexpected and paradoxical finding of increased hepatic DNA adducts of BP in CYP1A1 knockout mice also suggests that further study is warranted on the kinetics of metabolic clearance of PAHs and its impact on DNA adduct formation (Uno et al., 2001).

N-acetylation and aromatic amines

After cancer of the lung and bronchi, bladder cancer is the most prevalent tobacco related malignancy. A series of earlier studies suggested that differences in carcinogen-adduct levels can correlate closely to differences in bladder cancer risks that are determined both by carcinogen exposure intensity and metabolic genotype (Vineis and Martone, 1996; Vineis and Ronco, 1992). Generally these studies support the idea that adduct levels correlate with smoking related risk, particularly those differences in risk associated with smoking black (air cured) versus blonde (flue cured) tobacco. Protein–carcinogen adduction has been the focus of most of the research. Some potential inconsistencies were raised, however, in studies of DNA adducts. For example, no evidence of case control differences in urothelial cell DNA adduct levels were recorded in bladder biopsies (Talaska et al., 1994), nor were associations observed between 4-aminobiphenyl-DNA adduct levels and p53 mutations in bladder tumors (Martone et al., 1998). In urine, the major adduct forming species associated with smoking black tobacco was suggested to be PhIP (Peluso et al., 1991). More relevant to the more widely consumed flu cured tobacco is the identification of the putative N-(deoxyguanosin-8-yl)-4-aminobiphenyl DNA adduct in exfoliated bladder cells, the concentration of which was found to be related to the number of cigarettes smoked per day (Talaska et al., 1991).

Recently, in a case control study of bladder cancer, NAT2 slow acetylator genotypes were associated with increased aromatic DNA adducts in white blood cells from buffy coats obtained from cancer cases, but no such association was evident among the controls (Peluso et al., 2000). Researchers also reported that dietary fruits and vegetables were inversely related to adduct levels. Curiously, smoking was not found to be associated with the DNA adducts levels measured (Peluso et al., 2000). In the aforementioned case series of bladder cancer biopsies no association of NAT2 genotypes was observed with 4-ABP DNA adduct measurements although current smoking and smoking air cured tobacco were positively associated with increased adduct levels (Martone et al., 1998). NAT2 genotypes associated with slow acetylator phenotypes were associated with higher aromatic-DNA adduct levels (Hou et al., 2001; Matullo et al., 2001a). No effect of either NAT1 or NAT2 polymorphisms was found in an analysis of aromatic amine-DNA adducts in another study (Godschalk et al., 2001). These mixed results relating adduct measurements and NAT2 genotypes should be considered in light of the overall modest increase in risk for bladder cancer associated with polymorphisms at this locus indicated in a recent meta-analysis of epidemiologic studies (Marcus et al., 2000).

Quinone reductases and oxidative DNA damage

Only a few studies have examined DNA adducts in pancreatic tissues of smokers and non-smokers. One of these concluded that neither GSTM1 nor NQO1 modified DNA adducts related to oxidative stress (Kadlubar et al., 1998). This study must be considered preliminary with regard to the less prevalent genotypes (e.g. NQO1 and GSTT1 homozygous variant individuals), and more studies could be valuable. Cigarette smoking is one of only a few identified environmental risk factors for pancreatic cancer. A recent study (Duell et al., 2002) indicated an increased risk of GSTT1 null subjects among heavy smokers and perhaps a higher risk among women who were GSTT1 null and who smoked heavily.

A strong mechanistic rationale implicates metabolic polymorphisms in the formation of smoking related DNA adducts, however, the evidence supporting genetic modification of DNA adducts from cigarette smoking in vivo in man must be considered equivocal. Strong associations of CYP1A1 expression and enzyme activity with PAH–DNA adducts in vivo and negative or inconsistent findings with CYP1A1 genetic variants argues against the functional importance of the known CYP1A1 polymorphisms. Indeed, the relationships between the common genetic variations and enzyme inducibility is still unclear. Extensive characterization of the catalytic properties of GSTP1 variants and the weak or inconsistent relationships in vivo require further evaluation. Hemoglobin carcinogen adducts appear a better marker of biological effective dose for bladder cancer compared with DNA adducts.

DNA repair polymorphisms

XRCC1, XCRCC3, XPD, ERCC2, hOGG1, p53

While several epidemiological studies have implicated polymorphisms in DNA repair enzymes in cancers of the lung (Ratnasinghe et al., 2001; Park et al., 2002; Divine et al., 2001; David-Beabes and London, 2001; Butkiewicz et al., 2001; Cheng et al., 2000a; Sugimura et al., 1999), head and neck (Olshan et al., 2002; Sturgis et al., 1999) and bladder (Stern et al., 2001), several of these reports have indicated protective effects of alleles that are presumed to compromise DNA repair activities (David-Beabes and London, 2001; Olshan et al., 2002; Stern et al., 2001). One possible explanation for this apparent inconsistency, drawn from recent investigations of ultraviolet radiation related basal and squamous skin cancer, is that there are different effects of DNA damage in cells with intact apoptotic mechanisms versus those that have already lost the apoptotic response to DNA damage stimuli. Lower repair capacity could thus be protective for cancer, in that deficient cells would be targeted for cell death rather than survive and harbor deleterious mutations (Nelson et al., 2002). Such a model predicts interactions of DNA repair polymorphisms with tobacco carcinogen dose and/or dose intensity. Further study is obviously required, as both positive (Park et al., 2002) and negative interactions (David-Beabes and London, 2001) of heavy smoking and the XRCC1 Gln allele have already been recorded for lung cancer risk.

Although these epidemiologic observations make it problematic to formulate a priori hypotheses regarding DNA adducts and repair polymorphisms, several reports indicate increased adduct burdens in individuals who carry DNA repair variants. In a study of blood MNC DNA adducts with chromatographic properties similar to adducts detected in cells treated with simple phenols and quinones, researchers observed a significant association of the XRCC1 Gln allele with detectable DNA adduct levels. Adduct levels also showed a positive interaction with blood donor age but appeared unrelated to cigarette smoking (Duell et al., 2000). No association was observed for polymorphisms in the ERCC2 gene and phenol related adducts. Higher levels of bulky hydrophobic–DNA adducts were observed in white blood cells of non-smokers who were homozygous for the XRCC1 399Gln allele (Matullo et al., 2001b). In another study, XRCC3 variant alleles were associated with higher adduct levels in non-smokers (Matullo et al., 2001a). Among traffic exposed workers the XPD 751Gln allele was associated with higher adduct levels (Palli et al., 2001).

A polymorphism involving the endonuclease 8-oxo-guanine DNA glycosylase I (hOGG1;[C1245G;Exon7,Ser326Cys]) was not found to affect aromatic DNA adducts in pancreatic tissues (Li et al., 2002). No association of 8-oxo-dG levels and hOGG1 were found in lung tumor and normal lung tissue (Hardie et al., 2000). Recent work has questioned the functional importance of the hOGG1 Ser326Cys variant in repair of 8-oxo-dG lesions (Janssen, 2001, #399) and in lung cancer pathogenesis itself (Wikman et al., 2000). Finally, PAH–DNA adduct levels in white blood cells were suggested to be associated with the occurrence of a P53 polymorphism (Zhang et al., 2000).

These early studies suggest that DNA repair polymorphisms may help us to understand endogenous or age related DNA adduct formation and removal. More comprehensive studies of smokers are required to address the role of these genetic variants in smoking-induced DNA damage. Studying interactions among gene loci and carcinogen dose will require more sophisticated models and statistical analyses. At this time it is difficult to predict whether high risk genotypes will be associated with increased or decreased adduct level. The relationship may be different at early phases of a chronic exposure compared with later times and the establishment of genetically altered tissues.

New candidate gene polymorphisms

Additional polymorphic candidate genes with potential to modify tobacco related cancer risk via modulation of DNA adduct levels, include the phenol sulfotransferases such as SULT1A1 (Nowell et al., 2000), myeloperoxidase (Petruska et al., 1992; London et al., 1997; Le Marchand et al., 2000; Schabath et al., 2000; Misra et al., 2001; Rojas et al., 2001; Kantarci et al., 2002), dihydronicotinamide riboside (NRH)-quinone oxidoreductase 2 (NQQ2) (Jaiswal et al., 1999; Long and Jaiswal, 2000), UDP-glucuronosyl transferases (Ren et al., 2000; Grant and Bell, 2000; Yueh et al., 2001), and the transcription factor Nrf2, which is essential for inducible and constitutive expression of a group of detoxification and antioxidant enzymes (Aoki et al., 2001).

DNA adducts and cancer risk

Three lines of epidemiologic evidence implicate DNA adducts in the etiology of smoking related cancers. These include: case–control and cohort studies showing associations of cancer occurrence with smoking related DNA adducts, cancer risk associated with the induction of DNA adducts in biopsied cells, and correlative studies of adduct levels with exposures to known smoking carcinogens in target or surrogate tissues. The latter indirectly support a causal relationship of DNA adduct formation with cancer risk, Table 2.

Table 2 Studies of DNA adducts in tabacco related cancer risk

DNA adducts associated with lung cancer

Studies of DNA adducts in lung cancer patients have indicated higher adduct levels in lung tissue of cancer cases (Cheng et al., 2000b, 2001) and in their peripheral white blood cells (Vulimiri et al., 2000; Perera et al., 1989) compared with controls. Higher adduct levels were reported in lung tissue from women compared with men (Cheng et al., 2001). In a prospective study, researchers reported that increased adduct levels in white blood cells were associated with lung cancer risk among those who were current smokers at the time of blood sampling (Tang et al., 2001). A small cohort study of heavy smokers reported that high adduct levels in bronchoalveolar cells were associated with higher cancer mortality (Bonassi et al., 2001), though not specifically lung cancer. DNA adducts induced in vitro have been associated with lung cancer risk in case–control studies (Li et al., 2001b; Wei et al., 2000).

DNA adducts and cancers of the bladder, head and neck, pancreas and uterine cervix

DNA adduct levels in white blood cells were significantly associated with bladder cancer risk (Peluso et al., 1998, 2000). A series of studies have shown that smoking is associated with smoking related adducts in the oral cavity and larynx (Banaszewski et al., 2000; Szyfter et al., 1999a,b; Nath et al., 1998). In a case–control study, induced DNA adduct levels were found to be associated with risk of head and neck cancer (Li et al., 2001a). Particularly striking was the finding of specific adducts in gingival tissue derived from unsaturated aldehydes in cigarette smoke (Nath et al., 1998). A small study of pancreatic cancer patients reported higher levels of several DNA adduct species in nontumorous pancreatic tissues from cases compared with control tissues (Wang et al., 1998a). Smoking is a risk factor in cervical cancer and DNA adducts related to smoking have been observed in cervical cells of smokers (Melikian et al., 1999a). Interestingly, HPV infection appeared to enhance induction of DNA adducts by BPDE in cervical epithelial cells (Melikian et al., 1999b) suggesting a mechanism for the interaction of HPV and smoking in cervical cancer risk.

DNA-adducts and exposure to lung carcinogens

Studies of highly occupationally exposed populations have generally reported DNA adducts to be related to airborne PAH exposure but sorting out the independent effects of occupational and smoking related contributions to total PAH burdens has been problematic. Some exposures postulated to pose an increased risk for lung cancer have failed to lead to detectable increases in adduct levels. For example, among workers exposed to PAHs in carbon electrode manufacturing no correlations were found between DNA adducts and occupational PAH exposures (Arnould et al., 1999; van Delft et al., 1998b). In another study, and one of the only population based investigations on DNA adducts, researchers did not find that PAH–DNA adducts in blood lymphocytes correlated with differences in PAH exposure related to urban air pollution (Kyrtopoulos et al., 2001).

As indicated above, adduct levels in white blood cells have been associated with tobacco related cancer risk. Direct correlations among surrogate tissue and target tissues, however, are few in number. An early important observation was that smoking effects on adducts were stronger when measurements were made using DNA isolated from blood MNC compared with the DNA from the short-lived granulocyte fraction of WBC (Savela and Hemminki, 1991). In a subsequent study, hydrophobic-DNA adducts in blood MNCs were found to be a reliable surrogate of lung DNA adduct levels (Wiencke et al., 1995). Another researcher used induced sputum to assess smoking related DNA adducts (Nia et al., 2000). White blood cell adduct levels were shown to provide a suitable surrogate for DNA adducts in bronchoalveolar cells (Godschalk et al., 1998). The lung retains PAHs, and higher concentrations can be found in men compared with women, and perhaps among high risk ethnic minority groups (Seto et al., 1993; Goldman et al., 2001). Interestingly, concentrations of PAHs measured directly in lung tissue at autopsy were found to correlate well with PAH–DNA adduct levels measured in the same tissues (Lodovici et al., 1998). This observation suggests that exposed lung may constitute a tissue reservoir of unmetabolized PAHs. Immune cells from the peripheral blood or bronchoalveolar cells that migrate and circulate through lung tissue may be exposed to such accumulated PAHs. This may help explain the correlation of peripheral blood or bronchoalveolar cell DNA adduct levels with those measured in lung parenchyma and airways.

Dose response for DNA adducts and cigarette smoking

The nature of the dose–response for cigarette smoking and DNA adduct formation has significant implications in assessing cancer risks associated with tobacco use (Vineis et al., 2000). It is significant, therefore, that it is still somewhat unclear which measures of tobacco smoke exposure are most highly correlated with smoking related DNA adduct levels. Several studies now support the idea that current smokers have higher adduct levels compared with former smokers, and that daily cigarette consumption (cigarettes per day) is the most predictive measure of variations in adduct levels in target (Wiencke et al., 1999; Szyfter et al., 1999a; Banaszewski et al., 2000; Romano et al., 1999) and surrogate tissues of current smokers (Nia et al., 2000; Hou et al., 2001). In one study the daily cigarette tar consumed, but not the number of cigarettes, was found to be predictive of adduct levels in blood MNCs (Godschalk et al., 1998). Daily cigarette consumption in current smokers also predicted PAH–DNA adduct levels in cardiac tissue from patients undergoing open heart surgery (van Schooten et al., 1998). Nonetheless some investigations have reported higher levels of aromatic-DNA adducts in former smokers (Vulimiri et al., 2000). Earlier suggestions (Phillips et al., 1988) that DNA adducts may reflect lifetime cumulative tobacco smoke exposure as estimated by the pack–year variable do not appear to have been substantiated.

Few studies have examined predictors of adduct levels among former smokers specifically. One of the earliest studies of lung PAH–DNA adducts in former smokers reported that adduct levels were similar to those observed among never smokers after about 5 years of smoking cessation (Phillips et al., 1988). Later, a biphasic loss of PAH–DNA adducts was proposed that included a rapid initial phase followed by a second slower phase of adduct loss (Schoket et al., 1993). Studies of subjects in a smoking cessation program indicated an estimated half-life of PAH–DNA adducts of about 9–13 weeks in blood leukocytes (Mooney et al., 1995). The half-life of PAH–DNA adducts in the lung is probably much more protracted. One study of lung cancer patients indicated a half-life of approximately 1.7 years (Schoket et al., 1998) among short-term quitters. In a study of lung tissues from former smokers that included long-term quitters (>10 years), several statistical models were applied that suggested an approximate 10% decline in adducts per year for about 9 years and a much slower residual decline after 9 years (Thurston et al., 2000). Among these former smokers early age of smoking initiation was the most important predictor of interindividual variations in lung DNA adduct levels after adjusting for other measures of cigarette consumption (Wiencke et al., 1999). Aromatic-DNA adducts were also found to be increased in smokers who started smoking at an early age in another study (Vulimiri et al., 2000). Time elapsed since quitting smoking would seem a logical inverse predictor of DNA adducts in former smokers but this has not been reported. Although animal models have been used to address these questions (Helleberg et al., 2001; Izzotti et al., 1999) they do not take into account the protracted exposures typical in humans, nor the cellular and physiologic changes induced in tissues undergoing chronic exposure, which may modify adduct induction and repair. As indicated below, widespread accumulations of genetically altered clones of cells is known to occur in smokers chronically exposed to tobacco carcinogens (Franklin et al., 1997).

DNA adducts and somatic mutation in tumors

DNA adducts and p53

A review several years ago cited the need for human clinical studies of DNA adducts and the mutational spectra of cancer-relevant genes, and noted the paucity of studies in which mutations as a consequence of DNA damage at specific genes had been investigated in vivo (Kriek et al., 1998). This conclusion is still relevant today. The important mechanistic hypotheses on p53 mutational spectrum and smoking (see Hussain in this volume) raise significant challenges for clinical and epidemiological investigators to translate these insights into human populations. Early relatively small studies suggested that aromatic-DNA adduct levels were increased in tissues from patients with p53 mutant lung cancer compared with cases bearing non-p53 mutant tumors (Kure et al., 1996; Ryberg et al., 1997). Another study reported only a weak association between PAH–DNA adduct levels in lung tissue and p53 mutations (Andreassen et al., 1996). Our group found that lung cancer patients with high hydrophobic–DNA adduct levels in non-tumorous lung tissue (above the median adduct level) were threefold more likely to have a tumor containing a p53 mutation (Wiencke et al., 1998). This association was significant, even after adjusting for smoking status. In contrast, in a study of bladder cancer, 4-aminbiphenyl–DNA adducts were not found to be associated with the p53 mutational status of tumors (Martone et al., 1998). Larger studies with carefully collected smoking and lifestyle histories are necessary to define the relationship of DNA adduct burden in vivo and the p53 mutational status and spectra of human lung cancer.

DNA adducts and LOH at 3p21

An event more common than p53 mutation in lung cancer is the LOH and deletion of regions of the short-arm of chromosome 3 (e.g. 3p14, 3p12). LOH in these regions is strongly associated with smoking history (Nelson et al., 1998; Hirao et al., 2001; Zienolddiny et al., 2001) and is thought to be among the earliest events in lung carcinogenesis (Wistuba et al., 1999, 2000; Park et al., 1999; Endo et al., 2000; Mitsudomi et al., 1996). These early somatic events may be the molecular basis for what Slaughter first termed ‘field cancerization’. According to this idea, grossly normal epithelium can be ‘preconditioned’ by carcinogen exposure. Such preconditioning may result in early tobacco-induced somatic mutations that are propagated by enhanced cell replication into a clonal ‘field’ of genetically altered progenitor cells.

Consistent with these observations, we found a strong correlation of early age of smoking initiation with LOH at a loci near the hMLH1 gene on chromosome 3p21 in surgically resected lung cancer patients (Hirao et al., 2001). Interestingly, our investigations also revealed a link between these events and increased hydrophobic–DNA adduct levels in lung tissue from the same patients (Hirao et al., 2001). Another group, using microsatellite markers close to hMLH1, reported a similar increase in PAH–DNA adduct levels in lung tissues of lung cancer patients whose tumors contained LOH at 3p21 (Zienolddiny et al., 2001), although the question of age at smoking initiation was not addressed in the latter study. In a study of lymphocytes from lung cancer patients and controls, the highest aromatic DNA adduct levels were observed among cases who started smoking before 15 years of age (Vulimiri et al., 2000).

These links between DNA adducts and somatic alterations in the lung and early smoking initiation should be considered in light of the epidemiologic observations that early smoking initiation is an independent risk factor for lung cancer (Hegmann et al., 1993). Taken together these associations lead to a novel ‘critical period’ hypothesis for lung cancer susceptibility (Wiencke and Kelsey, 2002): growth and development of the lungs during adolescence may set up a critical period of susceptibility to tobacco-related DNA damage. This idea is consistent with the burst of lung growth that is known to occur in the early teen years. Exposure to tobacco carcinogens during this period may lead to the propagation of fields of altered epithelial cells, particularly in the airway, that later evolve into frank malignancy. Exposure after the critical growth period may have a much lower probability of inducing large, clonal outgrowths with the same malignant potential.

Emerging issues in tobacco carcinogenesis and DNAadducts

Endogenous adducts, oxidative DNA damage and indirect action

It has been suggested that damage to DNA from endogenous exposures may be orders of magnitude greater than those from exogenous sources including exposure to tobacco smoke (Povey, 2000). This does not imply, however, that endogenous agents do not play a role in tobacco carcinogenesis, because tobacco exposures can directly and indirectly increase oxidative stress. In animals, cigarette smoke exposures were shown to enhance endogenous DNA adducts by several fold in different tissues (Gupta et al., 1999; Zhou et al., 2000). Significant progress has been made in characterizing carbonyl-containing products of lipid peroxidation (e.g. malondialdehyde, 4-hydroxy-2-alkenals) and the adducts they form with DNA (Leuratti et al., 1998; Chen et al., 1998; Moller and Wallin, 1998; Yi et al., 1998) as well as the contributions of physiologic mediators such as nitric oxide in these reactions (Nair et al., 1998). The DNA adducts formed in reactions with carcinogenic aldehydes may produce structurally unique adducts (Hecht et al., 2001); these hold promise as sensitive markers of oral cancer risk associated with tobacco use (Nath et al., 1998). Some endogenously derived DNA adducts are thought to increase with age (Josyula et al., 2000; Yang et al., 1998). Several reviews have been presented on endogenous DNA adducts and cancer risk (Burcham, 1998; Bartsch and Nair, 2001; Blair, 2001).

Future studies of genetic susceptibility studies should consider the potential overlap between endogenous and exogenous pathways and sources of DNA adducts. For example, ethylene oxide, which is an endogenous metabolite of ethylene, is also present in cigarette smoke. Studies of blood hemoglobin adducts formed from ethylene oxide indicate that genetic deficiency in GSTT1 leads to higher adduct levels in smokers (Fennell et al., 2000) and non-smokers (Thier et al., 2001). DNA adducts in blood leukocytes were also reported to be higher in GSTT1 null subjects in the EPIC–Italy study (Palli et al., 2000).

Chemically unstable DNA adducts

The majority of studies of tobacco-related cancer and DNA adducts have focused on chemically stable modifications of DNA, like those produced by the reaction of BPDE with the exocyclic amino group of guanine. PAHs present in tobacco smoke, including BP, can also be metabolized via radical cation intermediates to electrophiles that bind to DNA bases and destabilize the N-glycosyl bond, causing rapid depurination or depyrimidination of the adducted bases (Bodell et al., 1989; Chen et al., 1996; Devanesan et al., 1996). In some experimental systems (e.g. mouse skin treated with BP) these unstable DNA adducts are much more prevalent than the stable DNA adducts. Understanding the relative importance of unstable versus stable adducts in tobacco carcinogenesis in humans and the role of DNA repair mechanisms that act on these different lesions will require further investigation (Melendez-Colon et al., 1997, 1999; Chakravarti et al., 2001). Future epidemiologic studies may be the only way to accurately assess the importance of depurinating adducts in tobacco carcinogenesis. This will require improvements in the methods for detecting such compounds in biological specimens. One sensitive method for detecting unstable DNA adducts in urine (i.e. using capillary electrophoresis–fluorescence line narrowing spectroscopy) has been developed (Roberts et al., 2000). Initial studies using this approach found BP adducted bases (e.g. BP-6 N7Gua) in the urine of three of seven cigarette smokers and three of seven women exposed to coal smoke, but none were detected in urine from 13 control subjects (Casale et al., 2001).

Factors affecting the validity of DNA adduct studies

Exposure misclassification, statistical analysis, study design

Others have reviewed some of the statistical and analytical issues that can compromise the validity of DNA adduct studies (Cuzick, 1995). The literature reviewed here alludes to a divergence in adduct results in current versus former smokers. This has important implications for the design of future investigations into the role of DNA adducts in tobacco-related cancer. At any single point in time the levels of tobacco-related DNA adducts in a human tissue represent a dynamic process that is dependent on a number of factors; these include the intensity and recency of exposure to tobacco smoke, the metabolic balance of activation and detoxification mechanisms and the repair or removal of adducts by DNA repair and/or cell turnover. Therefore, to observe relationships between putative modifiers of DNA adduct concentrations, it may be important to stratify on smoking status (current, former, never) in all statistical analyses or to employ multivariate statistical techniques that carefully address potential interactions of modifiers and smoking status. It may be expected, for example, that genetic modification of adduct levels arising through a metabolic mechanism (adduct formation) may be more evident among current smokers. Genetic factors affecting repair and tissue renewal (adduct removal) may be more evident in comparisons involving former smokers.

In addition, many of the case–control studies cited above can be criticized, on the basis that DNA adducts may be linked to cancer occurrence through their association with tobacco smoke exposure. As DNA adducts are thought to be part of the causal pathway in tobacco-related cancer they are not formally considered to be confounders. Nonetheless, these considerations raise concerns about the clinical value of DNA adducts as independent predictors of tobacco-related cancer risk. To mitigate against these concerns, the question of adducts as risk factors could be addressed in studies that carefully match cases and controls on cigarette smoking exposure. Case–control studies matching on smoking may also provide a more robust way to examine the role of candidate genes as modifiers of DNA adduct formation or repair. Because of the difficulty in recruiting suitable controls, however, such studies are more difficult to perform than traditional case–control studies.

Alternatives to case–control or cross-sectional studies include those employing prospective and interventional designs. For example, in the SELECT study (Selenium and Vitamin E Cancer Prevention Trial) the goal is to enroll 32 400 men aged 55 years and older and follow them for a 12 year study period (Hoque et al., 2001). Blood samples collected at baseline could be used for DNA adduct and candidate gene studies; an expected 800 lung cancer cases are predicted to occur within the study period.

Bias caused by seasonal variation in DNA adducts

Finally, a question still unresolved is whether studies of DNA adducts can be significantly biased by seasonal variations in adduct levels. Several studies have reported statistically significant variations in DNA adduct levels according to the season of study (Butkiewicz et al., 2000; Grzybowska et al., 1993; Moller et al., 1996; Motykiewicz et al., 1998; Palli et al., 2001; Perera et al., 1992; Tang et al., 1995; Topinka et al., 2000). Many of these reported higher ‘background’ adduct levels in winter compared with summer, and these variations appear to be related to the airborne concentrations of PAHs and nitro-PAHs, particularly for studies carried out in industrialized and polluted areas of Poland and the Czech Republic (Moller et al., 1996; Topinka et al., 2000). These observations suggest that seasonal variation in DNA adducts may not be a generalized phenomenon but is rather an issue that is regionally specific to those areas where ambient air quality varies widely with the season of the year.

However, recent research also indicates the complexities of these ecological associations. For example, concentrations of PAH–DNA adducts levels in WBCs were found to peak in Northern Italy (Turin, Varese) in winter and in summer in Central and Southern Italy (Florence, Naples, Ragusa), which suggested opposite seasonal trends according to latitude (Palli et al., 2000). The authors speculate that in summer photochemical pollution may be higher at lower latitudes and play a relatively greater role in the induction of adducts compared to the winter months. In another study, blood PAH–DNA adducts in non-smokers were found to be higher in the small Greek city of Halkida compared with adduct levels in non-smokers living in Athens, despite the far greater air pollution burden that exists in Athens (Kyrtopoulos et al., 2001). Consequently, it would appear prudent to consider seasonal information and ambient air quality in planning future studies to avoid potential biases that may arise from regional or seasonal variations in DNA adducts in human populations.

Abbreviations

GSTM1, GSTT1, GSTP1:

Glutathione S-transferase M1, T1, P1

NAT1, NAT2:

N-acetyltransferase type I and type II

NQQ1 :

NAD(P)H:quinone oxidoreductase type I

BP:

benzo(a)pyrene

BPDE:

7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9, 10-oxide

MNC:

mononuclear cells

PAH:

polynuclear aromatic hydrocarbons

GSH:

glutathione

HPLC:

high performance liquid chromatography

1-OHPY:

1-hydroxypyrene

WBC:

white blood cells

GS/MS:

gas chromatography-mass spectrometry

eA:

1,N6-ethenodeoxyadenosine

eC:

3,N4-etheneodeoxycytidine

M1G:

3-(2-deoxy-β-D-erythro-pentofuranosyl)pyrimido[1,2-α]purin-10(3H)-one

BP-6 N7Gua:

7-(benzo[a]pyren-6-yl)guanine

ELISA:

enzyme linked immunosorbent assay

8-oxo-dG:

8-hydroxy-2′-deoxyguanosine

PhIP:

2-amino-1-methyl-6-phenylimidazao[4,5-b]pyridine

HPV:

human papilloma virus

EPIC:

European Prospective Investigation into Cancer and Nutrition

References

  1. Alexandrov K, Rojas M, Geneste O, Castegnaro M, Camus AM, Petruzzelli S, Giuntini C, Bartsch H . 1992 Cancer Res. 52: 6248–6253

  2. Andreassen A, Kure EH, Nielsen PS, Autrup H, Haugen A . 1996 Mutat. Res. 368: 275–282

  3. Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, Yamamoto M . 2001 Toxicol. Appl. Pharmacol. 173: 154–160

  4. Arnould JP, Kubiak R, Belowski J, Belegaud J, Szczeklik J . 2000 Pathol. Bio. (Paris) 48: 548–553

  5. Arnould JP, Pfohl-Leszkowicz A, Bach V, Libert JP, Belegaud J . 1999 Hum. Exp. Toxicol. 18: 314–321

  6. Banaszewski J, Szmeja Z, Szyfter W, Szyfter K, Baranczewski P, Moller L . 2000 Eur. Arch. Otorhinolaryngol. 257: 149–153

  7. Bartsch H, Nair J . 2001 Adv. Exp. Med. Biol. 500: 675–686

  8. Bartsch H, Rojas M, Alexandrov K, Risch A . 1998 Recent Results Cancer Res. 154: 86–96

  9. Beserati Nia A, Van Straaten HW, Godschalk RW, Van Zandwijk N, Balm AJ, Kleinjans JC, Van Schooten FJ . 2000 Environ. Mol. Mutagen 36: 127–133

  10. Binkova B, Topinka J, Mrackova G, Gajdosova D, Vidova P, Stavkova Z, Peterka V, Pilcik T, Rimar V, Dobias L, Farmer PB, Sram RJ . 1998 Muta. Res. 416: 67–84

  11. Blair IA . 2001 Exp. Gerontol. 36: 1473–1481

  12. Bodell WJ, Devanesan PD, Rogan EG, Cavalieri EL . 1989 Chem. Res. Toxicol. 2: 312–315

  13. Bonassi S, Neri M, Puntoni R . 2001 Mutat. Res. 480–481: 349–358

  14. Bucci F, Galati R, Zito R, Falasca G, Federico A, Verdina A . 1998 Anticancer Res. 18: 2669–2674

  15. Burcham PC . 1998 Mutagenesis 13: 287–305

  16. Butkiewicz D, Grzybowska E, Phillips DH, Hemminki K, Chorazy M . 2000 Environ. Mol. Mutagen. 35: 99–105

  17. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC . 2001 Carcinogenesis 22: 593–597

  18. Carmichael PL . 1998 Arch. Toxicol. 20: Suppl 199–205

  19. Casale GP, Singhal M, Bhattacharya S, RamaNathan R, Roberts KP, Barbacci DC, Zhao J, Jankowiak R, Gross ML, Cavalieri EL, Small GJ, Rennard SI, Mumford JL, Shen M . 2001 Chem. Res. Toxicol. 14: 192–201

  20. Chakravarti D, Mailander PC, Li KM, Higginbotham S, Zhang HL, Gross ML, Meza JL, Cavalieri EL, Rogan EG . 2001 Oncogene 20: 7945–7953

  21. Chen HJ, Zhang L, Cox J, Cunningham JA, Chung FL . 1998 Chem. Res. Toxicol. 11: 1474–1480

  22. Chen L, Devanesan PD, Higginbotham S, Ariese F, Jankowiak R, Small GJ, Rogan EG, Cavalieri EL . 1996 Chem. Res. Toxicol. 9: 897–903

  23. Cheng L, Spitz MR, Hong WK, Wei Q . 2000a Carcinogenesis 21: 1527–1530

  24. Cheng YW, Chen CY, Lin P, Huang KH, Lin TS, Wu MH, Lee H . 2000b Eur. J. Cancer 36: 1381–1388

  25. Cheng YW, Hsieh LL, Lin PP, Chen CP, Chen CY, Lin TS, Su JM, Lee H . 2001 Environ. Mol. Mutagen. 37: 304–310

  26. Coles B, Yang M, Lang NP, Kadlubar FF . 2000a Cancer Lett. 156: 167–175

  27. Coles BF, Anderson KE, Doerge DR, Churchwell MI, Lang NP, Kadlubar FF . 2000b Cancer Res. 60: 573–579

  28. Cuzick J . 1995 J. Natl. Cancer Inst. 87: 861–862

  29. David-Beabes GL, London SJ . 2001 Lung Cancer 34: 333–339

  30. Devanesan PD, Higginbotham S, Ariese F, Jankowiak R, Suh M, Small GJ, Cavalieri EL, Rogan EG . 1996 Chem. Res. Toxicol. 9: 1113–1116

  31. Divine KK, Gilliland FD, Crowell RE, Stidley CA, Bocklage TJ, Cook DL, Belinsky SA . 2001 Mutat. Res. 461: 273–278

  32. Duell EJ, Holly EA, Bracci PM, Liu M, Wiencke JK, Kelsey KT . 2002 J. Natl. Cancer Inst. 94: 297–306

  33. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, Mark EJ, Wain JC, Christiani DC, Kelsey KT . 2000 Carcinogenesis 21: 965–971

  34. Endo C, Sato M, Fujimura S, Sakurada A, Aikawa H, Takahashi S, Usuda K, Saito Y, Sagawa M . 2000 Surg. Today 30: 695–699

  35. Fennell TR, MacNeela JP, Morris RW, Watson M, Thompson CL, Bell DA . 2000 Cancer Epidemiol. Biomarkers Prev. 9: 705–712

  36. Fields WR, Morrow CS, Doss AJ, Sundberg K, Jernstrom B, Townsend AJ . 1998 Mol. Pharmacol. 54: 298–304

  37. Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, Ritchey DM, Miller YE . 1997 J. Clin. Invest. 100: 2133–2137

  38. Garner RC . 1998 Mutat. Res. 402: 67–75

  39. Godschalk RW, Dallinga JW, Wikman H, Risch A, Kleinjans JC, Bartsch H, Van Schooten FJ . 2001 Pharmacogenetics 11: 389–398

  40. Godschalk RW, Maas LM, Van Zandwijk N, van't Veer LJ, Breedijk A, Borm PJ, Verhaert J, Kleinjans JC, van Schooten FJ . 1998 Carcinogenesis 19: 819–825

  41. Goldman R, Enewold L, Pellizzari E, Beach JB, Bowman ED, Krishnan SS, Shields PG . 2001 Cancer Res. 61: 6367–6371

  42. Grant DJ, Bell DA . 2000 Mol. Carcinog. 29: 198–204

  43. Grinberg-Funes RA, Singh VN, Perera FP, Bell DA, Young TL, Dickey C, Wang LW, Santella RM . 1994 Carcinogenesis 15: 2449–2454

  44. Grzybowska E, Butkiewicz D, Motykiewicz G, Chorazy M . 2000 Mutat. Res. 469: 271–277

  45. Grzybowska E, Hemminki K, Szeliga J, Chorazy M . 1993 Carcinogenesis 14: 2523–2526

  46. Gupta RC, Arif JM, Gairola CG . 1999 Mutat. Res. 424: 195–205

  47. Hardie LJ, Briggs JA, Davidson LA, Allan JM, King RF, Williams GI, Wild CP . 2000 Carcinogenesis 21: 167–172

  48. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR . 1997 Carcinogenesis 18: 641–644

  49. Hecht SS, McIntee EJ, Wang M . 2001 Toxicology 166: 31–36

  50. Hegmann KT, Fraser AM, Keaney RP, Moser SE, Nilasena DS, Sedlars M, Higham-Gren L, Lyon JL . 1993 Epidemiology 4: 444–448

  51. Helleberg H, Xu H, Ehrenberg L, Hemminki K, Rannug U, Tornqvist M . 2001 Mutagenesis 16: 333–337

  52. Hemminki K, Koskinen M, Rajaniemi H, Zhao C . 2000 Regul. Toxicol. Pharmacol. 32: 264–275

  53. Hemminki K, Koskinen M, Zhao C . 2001 Int. J. Cancer 92: 923–926

  54. Hirao T, Nelson HH, Ashok TD, Wain JC, Mark EJ, Christiani DC, Wiencke JK, Kelsey KT . 2001 Cancer Res. 61: 612–615

  55. Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, Thompson IM, Goodman P, Stanford JL, Crowley JJ, Coltman CA, Santella RM . 2001 Cancer Causes Control 12: 627–633

  56. Hou SM, Falt S, Yang K, Nyberg F, Pershagen G, Hemminki K, Lambert B . 2001 Cancer Epidemiol. Biomarkers Prev. 10: 133–140

  57. Hu X, Herzog C, Zimniak P, Singh SV . 1999 Cancer Res. 59: 2358–2362

  58. Izzotti A, Bagnasco M, D'Agostini F, Cartiglia C, Lubet RA, Kelloff GJ, De Flora S . 1999 Carcinogenesis 20: 1499–1505

  59. Jacobson JS, Begg MD, Wang LW, Wang Q, Agarwal M, Norkus E, Singh VN, Young TL, Yang D, Santella RM . 2000 Cancer Epidemiol. Biomarkers Prev. 9: 1303–1311

  60. Jaiswal AK, Bell DW, Radjendirane V, Testa JR . 1999 Pharmacogenetics 9: 413–418

  61. Josyula S, Schut HA, Diwan BA, Anver MR, Anderson LM . 2000 Int. J. Oncol. 17: 811–818

  62. Kadlubar FF, Anderson KE, Haussermann S, Lang NP, Barone GW, Thompson PA, MacLeod SL, Chou MW, Mikhailova M, Plastaras J, Marnett LJ, Nair J, Velic I, Bartsch H . 1998 Mutat. Res. 405: 125–133

  63. Kantarci OH, Lesnick TG, Yang P, Meyer RL, Hebrink DD, McMurray CT, Weinshenker BG . 2002 Mayo Clin. Proc. 77: 17–22

  64. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG . 1995 J. Natl. Cancer Inst. 87: 902–907

  65. Kihara M, Noda K . 1999 Cancer Lett. 137: 53–60

  66. Kriek E, Rojas M, Alexandrov K, Bartsch H . 1998 Mutat. Res. 400: 215–231

  67. Kure EH, Ryberg D, Hewer A, Phillips DH, Skaug V, Baera R, Haugen A . 1996 Carcinogenesis 17: 2201–2215

  68. Kyrtopoulos SA, Georgiadis P, Autrup H, Demopoulos N, Farmer P, Haugen A, Katsouyanni K, Lambert B, Ovrebo S, Sram R, Stefanou G, Topinka J . 2001 Mutat. Res. 496: 207–228

  69. Le Marchand L, Seifried A, Lum A, Wilkens LR . 2000 Cancer Epidemiol. Biomarkers Prev. 9: 181–184

  70. Leuratti C, Singh R, Lagneau C, Farmer PB, Plastaras JP, Marnet LJ, Shuker DE . 1998 Carcinogenesis 19: 1919–1924

  71. Li D, Firozi PF, Chang P, Wang LE, Xiong P, Sturgis EM, Eicher SA, Spitz MR, Hong WK, Wei Q . 2001a Int. J. Cancer 93: 436–440

  72. Li D, Firozi PF, Wang LE, Bosken CH, Spitz MR, Hong WK, Wei Q . 2001b Cancer Res. 61: 1445–1450

  73. Li D, Firozi PF, Zhang W, Shen J, DiGiovanni J, Lau S, Evans D, Friess H, Hassan M, Abbruzzese JL . 2002 Mutat. Res. 513: 37–48

  74. Lodovici M, Akpan V, Giovannini L, Migliani F, Dolara P . 1998 Chem. Biol. Interact. 116: 199–212

  75. London SJ, Lehman TA, Taylor JA . 1997 Cancer Res. 57: 5001–5003

  76. Long 2nd DJ, Jaiswal AK . 2000 Chem. Biol. Interact. 129: 99–112

  77. Marcus PM, Vineis P, Rothman N . 2000 Pharmacogenetics 10: 115–122

  78. Martone T, Airoldi L, Magagnotti C, Coda R, Randone D, Malaveille C, Avanzi G, Merletti F, Hautefeuille A, Vineis P . 1998 Int. J. Cancer 75: 512–516

  79. Marzilli LA, Koertje C, Vouros P . 2001 Methods Mol. Biol. 162: 395–406

  80. Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, Davico L, Piazza A, Vineis P . 2001a Int. J. Cancer 92: 562–567

  81. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, Krogh V, Munnia A, Tumino R, Polidoro S, Piazza A, Vineis P . 2001b Carcinogenesis 22: 1437–1445

  82. Melendez-Colon VJ, Luch A, Seidel A, Baird WM . 1999 Carcinogenesis 20: 1885–1891

  83. Melendez-Colon VJ, Smith CA, Seidel A, Luch A, Platt KL, Baird WM . 1997 Proc. Natl. Acad. Sci. USA 94: 13542–13547

  84. Melikian AA, Sun P, Prokopczyk B, El-Bayoumy K, Hoffman D, Wang X, Waggoner S . 1999a Cancer Lett. 146: 127–134

  85. Melikian AA, Wang X, Waggoner S, Hoffmann D, El-Bayoumy K . 1999b Oncol. Rep. 6: 1371–1376

  86. Misra RR, Tangrea JA, Virtamo J, Ratnasinghe D, Andersen MR, Barrett M, Taylor PR, Albanes D . 2001 Cancer Lett. 164: 161–167

  87. Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Sugio K, Yasumoto K, Sugimachi K, Gazdar AF . 1996 Clin. Cancer Res. 2: 1185–1189

  88. Moller L, Grzybowska E, Zeisig M, Cimander B, Hemminki K, Chorazy M . 1996 Carcinogenesis 17: 61–66

  89. Moller P, Wallin H . 1998 Mutat. Res. 410: 271–290

  90. Mollerup S, Ryberg D, Hewer A, Phillips DH, Haugen A . 1999 Cancer Res. 59: 3317–3320

  91. Mooney LA, Bell DA, Santella RM, Van Bennekum AM, Ottman R, Paik M, Blaner WS, Lucier GW, Covey L, Young TL, Cooper TB, Glassman AH, Perera FP . 1997 Carcinogenesis 18: 503–509

  92. Mooney LA, Santella RM, Covey L, Jeffrey AM, Bigbee W, Randall MC, Cooper TB, Ottman R, Tsai WY, Wazneh L et al . 1995 Cancer Epidemiol. Biomarkers Prev. 4: 627–634

  93. Motykiewicz G, Michalska J, Pendzich J, Malusecka E, Strozyk M, Kalinowska E, Butkiewicz D, Mielzynska D, Midro A, Santella RM, Chorazy M . 1998 Toxicol. Lett. 96–97: 195–202

  94. Nair J, Gal A, Tamir S, Tannenbaum SR, Wogan GN, Bartsch H . 1998 Carcinogenesis 19: 2081–2084

  95. Nath RG, Ocando JE, Guttenplan JB, Chung FL . 1998 Cancer Res. 58: 581–584

  96. Nelson HH, Kelsey KT, Mott LA, Karagas MR . 2002 Cancer Res. 62: 152–155

  97. Nelson HH, Wiencke JK, Gunn L, Wain JC, Christiani DC, Kelsey KT . 1998 Cancer Res. 58: 1804–1807

  98. Ni J, Liu T, Kolbanovskiy A, Krzeminski J, Amin S, Geacintov NE . 1998 Anal. Biochem. 264: 222–229

  99. Nia AB, Maas LM, Brouwer EM, Kleinjans JC, Van Schooten FJ . 2000 Carcinogenesis 21: 1335–1340

  100. Nowell S, Ambrosone CB, Ozawa S, MacLeod SL, Mrackova G, Williams S, Plaxco J, Kadlubar FF, Lang NP . 2000 Pharmacogenetics 10: 789–797

  101. Olshan AF, Watson MA, Weissler MC, Bell DA . 2002 Cancer Lett. 178: 181–186

  102. Ozawa S, Schoket B, McDaniel LP, Tang YM, Ambrosone CB, Kostic S, Vincze I, Kadlubar FF . 1999 Carcinogenesis 20: 991–995

  103. Palli D, Russo A, Masala G, Saieva C, Guarrera S, Carturan S, Munnia A, Matullo G, Peluso M . 2001 Int. J. Cancer 94: 121–127

  104. Palli D, Vineis P, Russo A, Berrino F, Krogh V, Masala G, Munnia A, Panico S, Taioli E, Tumino R, Garte S, Peluso M . 2000 Int. J. Cancer 87: 444–451

  105. Pan G, Hanaoka T, Yamano Y, Hara K, Ichiba M, Wang Y, Zhang J, Feng Y, Shujuan Z, Guan D, Gao G, Liu N, Takahashi K . 1998 Carcinogenesis 19: 1963–1968

  106. Park IW, Wistuba II, Maitra A, Milchgrub S, Virmani AK, Minna J, Gazdar AF . 1999 J. Natl. Cancer Inst. 91: 1863–1868

  107. Park JY, Lee SY, Jeon HS, Bae NC, Chae SC, Joo S, Kim CH, Park JH, Kam S, Kim IS, Jung TH . 2002 Cancer Epidemiol. Biomarkers Prev. 11: 23–27

  108. Pavanello S, Clonfero E . 2000 Mutat. Res. 463: 285–308

  109. Pavanello S, Favretto D, Brugnone F, Mastrangelo F, Dal Pra G, Clonfero E . 1999 Carcinogenesis 20: 431–435

  110. Peluso M, Airoldi L, Armelle M, Martone T, Coda R, Malaveille C, Giacomelli G, Terrone C, Casetta G, Vineis P . 1998 Cancer Epidemiol. Biomarkers Prev. 7: 341–346

  111. Peluso M, Airoldi L, Magagnotti C, Fiorini L, Munnia A, Hautefeuille A, Malaveille C, Vineis P . 2000 Carcinogenesis 21: 183–187

  112. Peluso M, Castegnaro M, Malaveille C, Friesen M, Garren L, Hautefeuille A, Vineis P, Kadlubar F, Bartsch H . 1991 Carcinogenesis 12: 713–717

  113. Perera F, Brenner D, Jeffrey A, Mayer J, Tang D, Warburton D, Young TI, Wazneh L, Latriano L, Motykiewicz G et al . 1992 Environ. Health Perspect. 98: 133–137

  114. Perera F, Mayer J, Jaretzki A, Hearne S, Brenner D, Young TL, Fischman HK, Grimes M, Grantham S, Tang MX, Tsai WY, Santella RM . 1989 Cancer Res. 49: 4446–4451

  115. Petruska JM, Mosebrook DR, Jakab GJ, Trush MA . 1992 Carcinogenesis 13: 1075–1081

  116. Petruzzelli S, Celi A, Pulera N, Baliva F, Viegi G, Carrozzi L, Ciacchini G, Bottai M, Di Pede F, Paoletti P, Giuntini C . 1998 Cancer Res. 58: 4122–4126

  117. Phillips DH, Castegnaro M . 1999 Mutagenesis 14: 301–315

  118. Phillips DH, Farmer PB, Beland FA, Nath RG, Poirier MC, Reddy MV, Turteltaub KW . 2000 Environ. Mol. Mutagen. 35: 222–233

  119. Phillips DH, Hewer A, Martin CN, Garner RC, King MM . 1988 Nature 336: 790–792

  120. Piipari R, Savela K, Nurminen T, Hukkanen J, Raunio H, Hakkola J, Mantyla T, Beaune P, Edwards RJ, Boobis AR, Anttila S . 2000 Int. J. Cancer 86: 610–616

  121. Povey AC . 2000 Toxicol. Pathol. 28: 405–414

  122. Ratnasinghe D, Yao SX, Tangrea JA, Qiao YL, Andersen MR, Barrett MJ, Giffen CA, Erozan Y, Tockman MS, Taylor PR . 2001 Cancer Epidemiol. Biomarkers Prev. 10: 119–123

  123. Reddy MV . 2000 Regul. Toxicol. Pharmacol. 32: 256–263

  124. Ren Q, Murphy SE, Zheng Z, Lazarus P . 2000 Drug Metab. Dispos. 28: 1352–1360

  125. Risch A, Wikman H, Thiel S, Schmezer P, Edler L, Drings P, Dienemann H, Kayser K, Schulz V, Spiegelhalder B, Bartsch H . 2001 Pharmacogenetics 11: 757–764

  126. Roberts KP, Lin CH, Singhal M, Casale GP, Small GJ, Jankowiak R . 2000 Electrophoresis 21: 799–806

  127. Rojas M, Alexandrov K, Cascorbi I, Brockmoller J, Likhachev A, Pozharisski K, Bouvier G, Auburtin G, Mayer L, Kopp-Schneider A, Roots I, Bartsch H . 1998 Pharmacogenetics 8: 109–118

  128. Rojas M, Cascorbi I, Alexandrov K, Kriek E, Auburtin G, Mayer L, Kopp-Schneider A, Roots I, Bartsch H . 2000 Carcinogenesis 21: 35–41

  129. Rojas M, Godschalk R, Alexandrov K, Cascorbi I, Kriek E, Ostertag J, Van Schooten FJ, Bartsch H . 2001 Carcinogenesis 22: 1015–1018

  130. Romano G, Sgambato A, Boninsegna A, Flamini G, Curigliano G, Yang Q, La Gioia V, Signorelli C, Ferro A, Capelli G, Santella RM, Cittadini A . 1999 Cancer Epidemiol. Biomarkers Prev. 8: 91–96

  131. Ryberg D, Hewer A, Phillips DH, Haugen A . 1994 Cancer Res. 54: 5801–5803

  132. Ryberg D, Skaug V, Hewer A, Phillips DH, Harries LW, Wolf CR, Ogreid D, Ulvik A, Vu P, Haugen A . 1997 Carcinogenesis 18: 1285–1289

  133. Saha BK, Bishayee A, Kanjilal NB, Chatterjee M . 2001 Cell Mol. Life Sci. 58: 1141–1149

  134. Savela K, Hemminki K . 1991 Carcinogenesis 12: 503–508

  135. Schabath MB, Spitz MR, Zhang X, Declos GL, Wu X . 2000 Carcinogenesis 21: 1163–1166

  136. Schoket B, Kostic S, Vincze I . 1993 IARC Sci. Publ. 124: 315–319

  137. Schoket B, Papp G, Levay K, Mrackova G, Kadlubar FF, Vincze I . 2001 Mutat. Res. 482: 57–69

  138. Schoket B, Phillips DH, Kostic S, Vincze I . 1998 Carcinogenesis 19: 841–846

  139. Seto H, Ohkubo T, Kanoh T, Koike M, Nakamura K, Kawahara Y . 1993 Arch. Environ. Contam. Toxicol. 24: 498–503

  140. Shields PG, Bowman ED, Harrington AM, Doan VT, Weston A . 1993 Cancer Res. 53: 3486–3492

  141. Shinozaki R, Inoue S, Choi KS . 1998 Cytometry 31: 300–306

  142. Shinozaki R, Inoue S, Choi KS, Tatsuno T . 1999 Arch. Environ. Health 54: 79–85

  143. Soni M, Madurantakan M, Krishnaswamy K . 1998 Toxicology 126: 155–162

  144. Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA . 2001 Cancer Epidemiol. Biomarkers Prev. 10: 125–131

  145. Sturgis EM, Castillo EJ, Li L, Zheng R, Eicher SA, Clayman GL, Strom SS, Spitz MR, Wei Q . 1999 Carcinogenesis 20: 2125–2129

  146. Sugimura H, Kohno T, Wakai K, Nagura K, Genka K, Igarashi H, Morris BJ, Baba S, Ohno Y, Gao C, Li Z, Wang J, Takezaki T, Tajima K, Varga T, Sawaguchi T, Lum JK, Martinson JJ, Tsugane S, Iwamasa T, Shinmura K, Yokota J . 1999 Cancer Epidemiol. Biomarkers Prev. 8: 669–674

  147. Sundberg K, Dreij K, Seidel A, Jernstrom B . 2002 Chem. Res. Toxicol. 15: 170–179

  148. Szeliga J, Dipple A . 1998 Chem. Res. Toxicol. 11: 1–11

  149. Szyfter K, Banaszewski J, Jaolszynski P, Pabiszczak M, Szyfter W, Szmeja Z . 1999a Acta Biochim. Pol. 46: 275–287

  150. Szyfter K, Szmeja Z, Szyfter W, Hemminki K, Banaszewski J, Jaskula-Sztul R, Louhelainen J . 1999b Mutat. Res. 445: 259–274

  151. Talaska G, al-Juburi AZ, Kadlubar FF . 1991 Proc. Natl. Acad. Sci. USA 88: 5350–5354

  152. Talaska G, Schamer M, Casetta G, Tizzani A, Vineis P . 1994 Cancer Lett. 84: 93–97

  153. Tan WG, Carnelley TJ, Murphy P, Wang H, Lee J, Barker S, Weinfeld M, Le XC . 2001 J. Chromatogr. A 924: 377–386

  154. Tang D, Phillips DH, Stampfer M, Mooney LA, Hsu Y, Cho S, Tsai WY, Ma J, Cole KJ, She MN, Perera FP . 2001 Cancer Res. 61: 6708–6712

  155. Tang D, Santella RM, Blackwood AM, Young TL, Mayer J, Jaretzki A, Grantham S, Tsai WY, Perera FP . 1995 Cancer Epidemiol. Biomarkers Prev. 4: 341–346

  156. Tang DL, Rundle A, Warburton D, Santella RM, Tsai WY, Chiamprasert S, Hsu YZ, Perera FP . 1998 Carcinogenesis 19: 1949–1953

  157. Thier R, Balkenhol H, Lewalter J, Selinski S, Dommermuth A, Bolt HM . 2001 Mutat. Res. 482: 41–46

  158. Thurston SW, Wand MP, Wiencke JK . 2000 Biometrics 56: 139–144

  159. Timbrell JA . 1998 Toxicology 129: 1–12

  160. Topinka J, Schwarz LR, Wiebel FJ, Cerna M, Wolff T . 2000 Mutat. Res. 469: 83–93

  161. Turteltaub KW, Dingley KH . 1998 Toxicol. Lett. 102–103: 435–439

  162. Uno S, Dalton TP, Shertzer HG, Genter MB, Warshawsky D, Talaska G, Nebert DW . 2001 Biochem. Biophys. Res. Commun. 289: 1049–1056

  163. Vainio H . 1998 Toxicol. Lett. 102–103: 581–589

  164. van Delft JH, Baan RA, Roza L . 1998a Crit. Rev. Toxicol. 28: 477–510

  165. van Delft JHG, Steenwinkel MS, van Asten JG, de Vogel N, Bruijntjes-Rozier TC, Schouten T, Cramer P, Maas L, van Herwijnen MH, van Schooten F, Hopmans PM . 2001 Ann. Occup. Hyg. 45: 395–408

  166. van Delft JH, Steenwinkel MJ, van Asten JG, van Es J, Kraak A, Baan RA . 1998b Ann. Occup. Hyg. 42: 105–114

  167. van Lieshout EM, Roelofs HM, Dekker S, Mulder CJ, Wobbes T, Jansen JB, Peters WH . 1999 Cancer Res. 59: 586–589

  168. Van Schooten FJ, Hirvonen A, Maas LM, De Mol BA, Kleinjans JC, Bell DA, Durrer JD . 1998 FASEB J. 12: 1409–1417

  169. Viezzer C, Norppa H, Clonfero E, Gabbani G, Mastrangelo G, Hirvonen A, Celotti L . 1999 Mutat. Res. 431: 259–269

  170. Vineis P, Kogevinas M, Simonato L, Brennan P, Boffetta P . 2000 Mutat. Res. 463: 103–110

  171. Vineis P, Martone T . 1996 Ann. Ist. Super Sanita 32: 21–27

  172. Vineis P, Ronco G . 1992 Environ. Health Perspect. 98: 95–99

  173. Vulimiri SV, Wu X, Baer-Dubowska W, de Andrade M, Detry M, Spitz MR, DiGiovanni J . 2000 Mol. Carcinog. 27: 34–46

  174. Wang M, Abbruzzese JL, Friess H, Hittelman WN, Evans DB, Abbruzzese MC, Chiao P, Li D . 1998a Cancer Res. 58: 38–41

  175. Wang Y, Ichiba M, Iyadomi M, Zhang J, Tomokuni K . 1998b Ind. Health 36: 337–346

  176. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA . 1998 Carcinogenesis 19: 275–280

  177. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, Spitz MR . 2000 J. Natl. Cancer Inst. 92: 1764–1772

  178. Whyatt RM, Bell DA, Jedrychowski W, Santella RM, Garte SJ, Cosma G, Manchester DK, Young TL, Cooper TB, Ottman R, Perera FP . 1998 Carcionogenesis 19: 1389–1392

  179. Whyatt RM, Perera FP, Jedrychowski W, Santella RM, Garte S, Bell DA . 2000 Cancer Epidemiol. Biomarkers Prev. 9: 207–221

  180. Whyatt RM, Jedruchowski W, Hemminki K, Santella RM, Tsai WY, Yang K, Perera FP . 2001 Cancer Epidemiol. Biomarkers Prev. 10: 581–588

  181. Wiencke JK, Kelsey KT, Varkonyi A, Semey K, Wain JC, Mark E, Christiani DC . 1995 Cancer Res. 55: 4910–4914

  182. Wiencke JK, Nelson H, Wain J, Mark E, Christiani DC, Kelsey KT . 1998 Association of increased PAH DNA adducts and p53 mutations in lung cancer. Proceedings of the 89th Annual Meeting of the American Association for Cancer Research 39: 1998 p 562

  183. Wiencke JK, Kelsey KT . 2002 Teen smoking, ‘field cancerization’ and a critical period hypothesis for lung cancer susceptibility Env. Health Perspect, June 2002

  184. Wiencke JK, Thurston SW, Kelsey KT, Varkonyi A, Wain JC, Mark EJ, Christiani DC . 1999 J. Natl. Cancer Inst. 91: 614–619

  185. Wikman H, Risch A, Klimek F, Schmezer P, Spiegelhalder B, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H . 2000 Int. J. Cancer 88: 932–937

  186. Williams MD, Sandler AB . 2001 Cancer Treat. Res. 105: 31–52

  187. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon 3rd JW, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF, Minna JD . 2000 Cancer Res. 60: 1949–1960

  188. Wistuba II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, Minna JD, Gazdar AF . 1999 Clin. Cancer Res. 5: 991–1000

  189. Xing JZ, Carnelley T, Lee J, Watson WP, Booth E, Weinfeld M, Le XC . 2001 Methods Mol. Biol. 162: 419–428

  190. Yang SC, Weinfeld M, Jenq SN, Kang ZC, Lee H . 2000 Chem. Res. Toxicol. 13: 1046–1050

  191. Yang K, Fang JL, Hemminki K . 1998 Mutat. Res. 422: 285–295

  192. Yi P, Sun X, Doerge DR, Fu PP . 1998 Chem. Res. Toxicol. 11: 1032–1041

  193. Yueh MF, Nguyen N, Famourzadeh M, Strassburg CP, Oda Y, Guengerich FP, Tukey RH . 2001 Carcinogenesis 22: 943–950

  194. Zhang J, Ichiba M, Feng Y, Pan G, Hanaoka T, Yamano Y, Hara K, Takahashi K, Tomokuni K . 2000 Int. Arch. Occup. Environ. Health 73: 127–135

  195. Zhou G, Hernandez NS, Randerath E, Randerath K . 2000 Mutat. Res. 447: 137–147

  196. Zienolddiny S, Ryberg D, Arab MO, Skaug V, Haugen A . 2001 Br. J. Cancer 84: 226–231

Download references

Acknowledgements

This work was supported by NIH ES06717.

Author information

Affiliations

Authors

Corresponding author

Correspondence to John K Wiencke.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wiencke, J. DNA adduct burden and tobacco carcinogenesis. Oncogene 21, 7376–7391 (2002). https://doi.org/10.1038/sj.onc.1205799

Download citation

Keywords

  • DNA adducts
  • tobacco
  • risk assessment
  • molecular epidemiology

Further reading